AnaptysBio Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

AnaptysBioDer Gewinn des Unternehmens wird voraussichtlich um 14.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 10.6% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-14.9%

Wachstumsrate der Gewinne

-1.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	10.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12

Recent updates

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

Nov 21

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Nov 07

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Sep 14

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Sep 12

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

Sep 01

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Aug 31

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ANAB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	56	-231	-251	-206	9
12/31/2025	44	-213	-143	-180	12
12/31/2024	58	-171	-12	-101	12
9/30/2024	57	-166	-103	-103	N/A
6/30/2024	30	-170	-130	-129	N/A
3/31/2024	23	-163	-134	-133	N/A
12/31/2023	17	-164	-122	-121	N/A
9/30/2023	15	-148	-98	-97	N/A
6/30/2023	13	-144	-79	-78	N/A
3/31/2023	11	-137	-78	-77	N/A
12/31/2022	10	-129	-74	-74	N/A
9/30/2022	4	-135	-88	-88	N/A
6/30/2022	24	-108	-78	-77	N/A
3/31/2022	53	-76	-45	-44	N/A
12/31/2021	63	-58	-47	-46	N/A
9/30/2021	122	8	15	17	N/A
6/30/2021	101	-9	5	7	N/A
3/31/2021	71	-30	-23	-22	N/A
12/31/2020	75	-20	-15	-14	N/A
9/30/2020	18	-74	-68	-68	N/A
6/30/2020	18	-81	-73	-73	N/A
3/31/2020	23	-84	-69	-69	N/A
12/31/2019	8	-97	-70	-70	N/A
9/30/2019	5	-94	-67	-66	N/A
6/30/2019	10	-79	-60	-59	N/A
3/31/2019	5	-69	-53	-52	N/A
12/31/2018	5	-62	-50	-49	N/A
9/30/2018	8	-52	-42	-41	N/A
6/30/2018	3	-45	N/A	-30	N/A
3/31/2018	10	-34	N/A	-24	N/A
12/31/2017	10	-30	N/A	-19	N/A
9/30/2017	10	-27	N/A	-20	N/A
6/30/2017	13	-19	N/A	-19	N/A
3/31/2017	12	-15	N/A	-15	N/A
12/31/2016	17	-4	N/A	-9	N/A
9/30/2016	18	-4	N/A	-6	N/A
6/30/2016	19	-4	N/A	-5	N/A
3/31/2016	18	-6	N/A	-9	N/A
12/31/2015	18	-5	N/A	-10	N/A
9/30/2015	17	-2	N/A	-6	N/A
6/30/2015	19	0	N/A	-4	N/A
3/31/2015	18	1	N/A	-3	N/A
12/31/2014	16	0	N/A	15	N/A
12/31/2013	5	-6	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ANAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ANAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ANAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ANABDie Einnahmen des Unternehmens (10.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: ANABDie Einnahmen des Unternehmens (10.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ANAB in 3 Jahren voraussichtlich hoch sein wird

AnaptysBio Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 70%

Consensus revenue estimates fall by 20%

Price target increased by 10% to US$48.22

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 48%

Recent updates

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Consensus revenue estimates increase by 70%

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Chief Legal Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Consensus revenue estimates fall by 20%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 10% to US$48.22

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Consensus revenue estimates increase by 48%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

No longer forecast to breakeven

Price target increased by 27% to US$35.83

President exercised options and sold US$150k worth of stock

Consensus revenue estimates increase by 27%

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 16%

Price target decreased by 10% to US$26.80

Price target decreased by 12% to US$28.20

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Chief Financial Officer exercised options and sold US$116k worth of stock

AnaptysBio, Inc. Announces Board Changes

High number of new directors

Consensus revenue estimates decrease by 18%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Forecast to breakeven in 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 43%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2025

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Consensus forecasts updated

Price target increased to US$31.50

Price target increased to US$31.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Consensus revenue estimates increase by 58%

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Consensus revenue estimates increase by 17%

Price target decreased to US$29.33

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Consensus revenue estimates fall by 10%

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa